Aydin Huseynov
Stock Analyst at Ladenburg Thalmann & Co.
(0.08)
# 4,405
Out of 4,455 analysts
118
Total ratings
32.3%
Success rate
-18.7%
Average return
Main Sectors:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiated Coverage: Buy | $4 | $1.91 | +109.42% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiated Coverage: Buy | $40 | $10.73 | +272.79% | 1 | Jan 5, 2026 | |
| URGN UroGen Pharma | Reiterated: Buy | $31 → $55 | $34.54 | +59.24% | 2 | Nov 7, 2025 | |
| IMUX Immunic | Initiated Coverage: Buy | $30 | $15.30 | +96.08% | 1 | Oct 16, 2025 | |
| KALA KALA BIO | Initiated Coverage: Buy | $600 | $2.52 | +23,709.52% | 1 | Jul 11, 2025 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $39 → $48 | $26.44 | n/a | 4 | Mar 20, 2025 | |
| ARDX Ardelyx | Maintained: Buy | $11 | $5.55 | n/a | 1 | Mar 7, 2025 | |
| BDRX Biodexa Pharmaceuticals | Maintained: Buy | $8 → $18 | $2.92 | n/a | 2 | Jan 2, 2025 | |
| CLRB Cellectar Biosciences | Maintained: Buy | $390 | $2.52 | n/a | 1 | Dec 5, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintained: Buy | $21 → $24 | $13.49 | n/a | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $7 | $2.08 | n/a | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $19 | $1.32 | n/a | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $1.68 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.19 | n/a | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $1.12 | n/a | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $0.1631 | n/a | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $12.46 | n/a | 2 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $6 | $12.39 | n/a | 4 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $19 | $0.9712 | n/a | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $55.11 | n/a | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $10 | $1.08 | n/a | 3 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $27.19 | n/a | 2 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $5.35 | n/a | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $10 | $4.82 | n/a | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $240 | $1.89 | n/a | 3 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.45 | n/a | 3 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.43 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0004 | n/a | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.65 | n/a | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.30 | n/a | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $1.72 | n/a | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $632.90 | n/a | 11 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $26 → $20 | $63.65 | n/a | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $81.18 | n/a | 5 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $89 | $113.75 | n/a | 5 | Sep 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $3.59 | n/a | 5 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $5.52 | n/a | 2 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.86 | n/a | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $15 | $1.10 | n/a | 7 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $168.52 | n/a | 1 | Sep 30, 2020 |
Inhibikase Therapeutics
Mar 4, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $1.91
Upside: +109.42%
Akari Therapeutics,
Jan 5, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $10.73
Upside: +272.79%
UroGen Pharma
Nov 7, 2025
Reiterated: Buy
Price Target: $31 → $55
Current: $34.54
Upside: +59.24%
Immunic
Oct 16, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $15.30
Upside: +96.08%
KALA BIO
Jul 11, 2025
Initiated Coverage: Buy
Price Target: $600
Current: $2.52
Upside: +23,709.52%
Capricor Therapeutics
Mar 20, 2025
Reiterated: Buy
Price Target: $39 → $48
Current: $26.44
Upside: n/a
Ardelyx
Mar 7, 2025
Maintained: Buy
Price Target: $11
Current: $5.55
Upside: n/a
Biodexa Pharmaceuticals
Jan 2, 2025
Maintained: Buy
Price Target: $8 → $18
Current: $2.92
Upside: n/a
Cellectar Biosciences
Dec 5, 2024
Maintained: Buy
Price Target: $390
Current: $2.52
Upside: n/a
Corvus Pharmaceuticals
Nov 13, 2024
Maintained: Buy
Price Target: $21 → $24
Current: $13.49
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $5 → $7
Current: $2.08
Upside: n/a
Oct 21, 2024
Maintained: Buy
Price Target: $11 → $19
Current: $1.32
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $16
Current: $1.68
Upside: n/a
Aug 14, 2024
Reiterated: Buy
Price Target: $7
Current: $1.19
Upside: n/a
Jul 30, 2024
Maintained: Buy
Price Target: $6 → $5
Current: $1.12
Upside: n/a
Jun 27, 2024
Initiated Coverage: Buy
Price Target: $10
Current: $0.1631
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: n/a
Current: $12.46
Upside: n/a
May 16, 2024
Maintained: Buy
Price Target: $8 → $6
Current: $12.39
Upside: n/a
Apr 18, 2024
Maintained: Buy
Price Target: $9 → $19
Current: $0.9712
Upside: n/a
Mar 14, 2024
Downgraded: Hold
Price Target: n/a
Current: $55.11
Upside: n/a
Nov 10, 2023
Reiterated: Buy
Price Target: $14 → $10
Current: $1.08
Upside: n/a
Nov 9, 2023
Reiterated: Buy
Price Target: $21
Current: $27.19
Upside: n/a
Oct 10, 2023
Initiated Coverage: Buy
Price Target: $10
Current: $5.35
Upside: n/a
Jun 5, 2023
Maintained: Buy
Price Target: $20 → $10
Current: $4.82
Upside: n/a
May 16, 2023
Maintained: Buy
Price Target: $25 → $240
Current: $1.89
Upside: n/a
Mar 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $4.45
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $6
Current: $1.43
Upside: n/a
Nov 15, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.0004
Upside: n/a
Nov 4, 2022
Downgraded: Hold
Price Target: n/a
Current: $1.65
Upside: n/a
Aug 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $1.30
Upside: n/a
May 2, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $1.72
Upside: n/a
Nov 9, 2021
Maintained: Hold
Price Target: n/a
Current: $632.90
Upside: n/a
Nov 8, 2021
Upgraded: Buy
Price Target: $26 → $20
Current: $63.65
Upside: n/a
Oct 21, 2021
Maintained: Hold
Price Target: n/a
Current: $81.18
Upside: n/a
Sep 23, 2021
Maintained: Buy
Price Target: $89
Current: $113.75
Upside: n/a
Sep 20, 2021
Maintained: Buy
Price Target: $9
Current: $3.59
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $5
Current: $5.52
Upside: n/a
Jun 21, 2021
Reiterated: Buy
Price Target: $15
Current: $1.86
Upside: n/a
Jan 8, 2021
Maintained: Buy
Price Target: $25 → $15
Current: $1.10
Upside: n/a
Sep 30, 2020
Initiated Coverage: Hold
Price Target: n/a
Current: $168.52
Upside: n/a